인쇄하기
취소

Gap among BMS, Gilead and Abbvie over hepatitis C treatments

Published: 2015-08-10 10:37:58
Updated: 2015-08-10 10:37:58

Oral hepatitis C treatments needing no interferon are getting close to commercialization.

In the domestic market, the closest company to commercialization is BMS. The company has acquired an approval for the NS5A replication complex inhibitor ‘Daklinza(daclatasvir)’ in combination with the NS3/4A protease inhibitor ‘Sunvepra(asunaprevir)’ from the Ministry of Food and Drug Safety last April.

...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.